Downregulation of the KIP family members p27KIP1 and p57KIP2 by SKP2 and the role of methylation in p57KIP2 inactivation in nonsmall cell lung cancer
Open Access
- 20 October 2006
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 119 (11) , 2546-2556
- https://doi.org/10.1002/ijc.22214
Abstract
Knowing the status of molecules involved in cell cycle control in cancer is vital for therapeutic approaches aiming at their restoration. The p27KIP1 and p57KIP2 cyclin‐dependent kinase inhibitors are nodal factors controlling normal cell cycle. Their expression in normal lung raises the question whether they have a mutual exclusive or redundant role in nonsmall cell lung cancer (NSCLC). A comparative comprehensive analysis was performed in a series of 70 NSCLCs. The majority of cases showed significantly reduced expression of both members compared to normal counterparts. Low KIP protein levels correlated with increased proliferation, which seems to be histological subtype preponderant. At mechanistic level, degradation by SKP2 was demonstrated, in vivo and in vitro, by siRNA‐methodology, to be the most important downregulating mechanism of both KIPs in NSCLC. Decreased p57KIP2‐transcription complements the above procedure in lowering p57KIP2‐protein levels. Methylation was the main cause of decreased p57KIP2‐mRNA levels. Allelic loss and imprinting from LIT1 mRNA contribute also to decreased p57KIP2 transcription. In vitro recapitulation of the in vivo findings, in A549 lung cells (INK4A‐B(−/−)), suggested that inhibition of the SKP2‐degradation mechanism restores p27KIP1 and p57KIP2 expression. Double siRNA treatments demonstrated that each KIP is independently capable of restraining cell growth. An additional demethylation step is required for complete reconstitution of p57KIP2 expression in NSCLC.Keywords
This publication has 57 references indexed in Scilit:
- Immunohistochemical analysis of P57(kip2), p53 and hsp60 expressions in premalignant and malignant oral tissuesOral Oncology, 2006
- Expression of p57/Kip2 Protein in Hepatocellular CarcinomaOncology, 2001
- Low Levels of p27 in Association With Deregulated p53-pRb Protein Status Enhance Tumor Proliferation and Chromosomal Instability in Non-Small Cell Lung CarcinomasMolecular Medicine, 2001
- Regulation of the Cell Cycle at the G1–S Transition by Proteolysis of Cyclin E and p27Kip1Biochemical and Biophysical Research Communications, 2001
- Spatial and temporal expression patterns of the cyclin-dependent kinase (CDK) inhibitors p27 Kip1 and p57 Kip2 during mouse developmentBrain Structure and Function, 2001
- Reduced expression of p27/Kip1 is associated with the development of pulmonary adenocarcinomaThe Journal of Pathology, 2000
- CDK inhibitors: positive and negative regulators of G1-phase progressionGenes & Development, 1999
- Altered cell differentiation and proliferation in mice lacking p57KIP2 indicates a role in Beckwith–Wiedemann syndromeNature, 1997
- Ablation of the CDK inhibitor p57Kip2 results in increased apoptosis and delayed differentiation during mouse development.Genes & Development, 1997
- Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution.Genes & Development, 1995